Human Induced Pluripotent Stem Cells as a Platform for Personalized and Precision Cardiovascular Medicine.
暂无分享,去创建一个
[1] U. Landmesser,et al. Restrictive cardiomyopathy , 2017, Wiener klinische Wochenschrift.
[2] Divya Rajamohan,et al. Cardiomyocytes from human pluripotent stem cells: From laboratory curiosity to industrial biomedical platform☆ , 2016, Biochimica et biophysica acta.
[3] I. Y. Chen,et al. Induced pluripotent stem cells: at the heart of cardiovascular precision medicine , 2016, Nature Reviews Cardiology.
[4] Russ B Altman,et al. Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity , 2016, Nature Medicine.
[5] Nazish Sayed,et al. Translation of Human-Induced Pluripotent Stem Cells: From Clinical Trial in a Dish to Precision Medicine. , 2016, Journal of the American College of Cardiology.
[6] Tanuj Kanchan,et al. Human Genome Editing and Ethical Considerations , 2015, Science and Engineering Ethics.
[7] W. Riley,et al. Precision Public Health for the Era of Precision Medicine. , 2016, American journal of preventive medicine.
[8] Md. Abul Hassan Samee,et al. Complex Interdependence Regulates Heterotypic Transcription Factor Distribution and Coordinates Cardiogenesis , 2016, Cell.
[9] J. Vockley,et al. Precision medicine in the age of big data: The present and future role of large‐scale unbiased sequencing in drug discovery and development , 2016, Clinical pharmacology and therapeutics.
[10] E. Schulze-Bahr,et al. Human iPS cell model of type 3 long QT syndrome recapitulates drug-based phenotype correction , 2016, Basic Research in Cardiology.
[11] C. Siu,et al. Efficient attenuation of Friedreich's ataxia (FRDA) cardiomyopathy by modulation of iron homeostasis-human induced pluripotent stem cell (hiPSC) as a drug screening platform for FRDA. , 2016, International journal of cardiology.
[12] Praveen Shukla,et al. Engineered heart tissues and induced pluripotent stem cells: Macro- and microstructures for disease modeling, drug screening, and translational studies. , 2016, Advanced drug delivery reviews.
[13] Timothy J. Nelson,et al. Modeling structural and functional deficiencies of RBM20 familial dilated cardiomyopathy using human induced pluripotent stem cells. , 2016, Human molecular genetics.
[14] J. Pritchard,et al. Genetic Variation, Not Cell Type of Origin, Underlies the Majority of Identifiable Regulatory Differences in iPSCs , 2016, PLoS genetics.
[15] P. Burridge,et al. Modeling Cardiovascular Diseases with Patient-Specific Human Pluripotent Stem Cell-Derived Cardiomyocytes. , 2016, Methods in molecular biology.
[16] S. Yamanaka,et al. From Genomics to Gene Therapy: Induced Pluripotent Stem Cells Meet Genome Editing. , 2015, Annual review of genetics.
[17] P. Burridge,et al. Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and Differentiation in Regenerative Medicine. , 2015, Annual review of genetics.
[18] Behnam Ebrahimi,et al. Reprogramming barriers and enhancers: strategies to enhance the efficiency and kinetics of induced pluripotency , 2015, Cell Regeneration.
[19] M. Alexander,et al. Scaling human pluripotent stem cell expansion and differentiation: are cell factories becoming a reality? , 2015, Regenerative medicine.
[20] F. Sasarman,et al. Mitochondrial Diseases and Cardiomyopathies. , 2015, The Canadian journal of cardiology.
[21] A. Mani,et al. The Genetic Challenges and Opportunities in Advanced Heart Failure. , 2015, The Canadian journal of cardiology.
[22] J. Rinn,et al. A comparison of genetically matched cell lines reveals the equivalence of human iPSCs and ESCs , 2015, Nature Biotechnology.
[23] Gregory F. Lewis,et al. High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays. , 2015, Toxicology and applied pharmacology.
[24] S. Haupt,et al. A reproducible and versatile system for the dynamic expansion of human pluripotent stem cells in suspension. , 2015, Biotechnology journal.
[25] P. Burridge,et al. Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells , 2015, Current protocols in human genetics.
[26] T. Cathomen,et al. Proven and novel strategies for efficient editing of the human genome. , 2015, Current opinion in pharmacology.
[27] Kin-Fan Au,et al. PacBio Sequencing and Its Applications , 2015, Genom. Proteom. Bioinform..
[28] Don Paul Kovarcik,et al. cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications , 2015, Stem cell reports.
[29] M. Gollob,et al. Genetics of inherited primary arrhythmia disorders , 2015, The application of clinical genetics.
[30] C. Pc,et al. The human subject: an integrative animal model for 21(st) century heart failure research. , 2015 .
[31] P. Shen,et al. A Rapid, High-Quality, Cost-Effective, Comprehensive and Expandable Targeted Next-Generation Sequencing Assay for Inherited Heart Diseases. , 2015, Circulation research.
[32] E. Amsterdam,et al. The Epidemiology, Clinical Manifestations, and Management of Chagas Heart Disease , 2015, Clinical cardiology.
[33] G. Stacey,et al. Impact of National and International Stem Cell Banking Initiatives on progress in the field of cell therapy: IABS-JST Joint Workshop: Summary for Session 5. , 2015, Biologicals : journal of the International Association of Biological Standardization.
[34] Praveen Shukla,et al. Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. , 2015, Stem cell research.
[35] Alexander Meissner,et al. Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells , 2015, Nature Methods.
[36] F. Charpentier,et al. Toward Personalized Medicine: Using Cardiomyocytes Differentiated From Urine-Derived Pluripotent Stem Cells to Recapitulate Electrophysiological Characteristics of Type 2 Long QT Syndrome , 2015, Journal of the American Heart Association.
[37] George Church,et al. Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated cardiomyopathy , 2015, Science.
[38] Daniel Spies,et al. Dynamics in Transcriptomics: Advancements in RNA-seq Time Course and Downstream Analysis , 2015, Computational and structural biotechnology journal.
[39] Y. Eto,et al. Disease modeling and lentiviral gene transfer in patient-specific induced pluripotent stem cells from late-onset Pompe disease patient , 2015, Molecular therapy. Methods & clinical development.
[40] Michael Eldar,et al. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations , 2015, Journal of cellular and molecular medicine.
[41] Donald M Bers,et al. Epigenetic Regulation of Phosphodiesterases 2A and 3A Underlies Compromised β-Adrenergic Signaling in an iPSC Model of Dilated Cardiomyopathy. , 2015, Cell stem cell.
[42] Xiaofang Sun,et al. Effects of Integrating and Non-Integrating Reprogramming Methods on Copy Number Variation and Genomic Stability of Human Induced Pluripotent Stem Cells , 2015, PloS one.
[43] I. Karakikes,et al. Induced Pluripotent Stem Cell–Derived Cardiomyocytes: A New and Versatile Human In Vitro Cardiomyocyte Model Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Insights Into Molecular, Cellular, and Functional Phenotypes , 2015 .
[44] B. Malgrange,et al. Generation of Isogenic Human iPS Cell Line Precisely Corrected by Genome Editing Using the CRISPR/Cas9 System , 2015, Stem Cell Reviews and Reports.
[45] Philip T Sager,et al. Finding the rhythm of sudden cardiac death: new opportunities using induced pluripotent stem cell-derived cardiomyocytes. , 2015, Circulation research.
[46] M. Snyder,et al. High-throughput sequencing technologies. , 2015, Molecular cell.
[47] Jacqueline Corrigan-Curay,et al. Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014. , 2015, Molecular therapy : the journal of the American Society of Gene Therapy.
[48] S. Barlas. Precision medicine initiative aims for a new generation of diagnostics and treatments: but is the promise of genetic targeting overinflated? , 2015, P & T : a peer-reviewed journal for formulary management.
[49] G. Bett,et al. Modeling and study of the mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from individuals with Duchenne muscular dystrophy , 2015, Disease Models & Mechanisms.
[50] Ronald A. Li,et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy , 2015, Nature Communications.
[51] Y. Pinto,et al. Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. , 2015, Cardiovascular research.
[52] Darren R. Williams,et al. Making cardiomyocytes with your chemistry set: Small molecule-induced cardiogenesis in somatic cells. , 2015, World journal of cardiology.
[53] Stuart A Cook,et al. Characterization of a novel KCNQ1 mutation for type 1 long QT syndrome and assessment of the therapeutic potential of a novel IKs activator using patient-specific induced pluripotent stem cell-derived cardiomyocytes , 2015, Stem Cell Research & Therapy.
[54] Bruce R. Conklin,et al. A Non-invasive Platform for Functional Characterization of Stem-Cell-Derived Cardiomyocytes with Applications in Cardiotoxicity Testing , 2015, Stem cell reports.
[55] Eli R. Zunder,et al. A continuous molecular roadmap to iPSC reprogramming through progression analysis of single-cell mass cytometry. , 2015, Cell stem cell.
[56] Arthur S Slutsky,et al. Preclinical target validation using patient-derived cells , 2015, Nature Reviews Drug Discovery.
[57] F. Collins,et al. A new initiative on precision medicine. , 2015, The New England journal of medicine.
[58] Moritoshi Sato,et al. CRISPR-Cas9-based photoactivatable transcription system. , 2015, Chemistry & biology.
[59] Robert Passier,et al. Atrial-like cardiomyocytes from human pluripotent stem cells are a robust preclinical model for assessing atrial-selective pharmacology , 2015, EMBO molecular medicine.
[60] Marius Wernig,et al. Early reprogramming regulators identified by prospective isolation and mass cytometry , 2015, Nature.
[61] A. Lindahl,et al. Identification of novel biomarkers for doxorubicin-induced toxicity in human cardiomyocytes derived from pluripotent stem cells , 2015, Toxicology.
[62] Alexandro E. Trevino,et al. Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.
[63] M. Kay,et al. Novel codon-optimized mini-intronic plasmid for efficient, inexpensive, and xeno-free induction of pluripotency , 2015, Scientific Reports.
[64] Mark D. Huffman,et al. AHA Statistical Update Heart Disease and Stroke Statistics — 2012 Update A Report From the American Heart Association WRITING GROUP MEMBERS , 2010 .
[65] Y. Usson,et al. Modular organization of cardiac energy metabolism: energy conversion, transfer and feedback regulation , 2015, Acta physiologica.
[66] J. Pippin,et al. The human subject: an integrative animal model for 21(st) century heart failure research. , 2015, American journal of translational research.
[67] James A Thomson,et al. Pompe Disease Results in a Golgi-based Glycosylation Deficit in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes* , 2014, The Journal of Biological Chemistry.
[68] D. Malan,et al. Robust Generation of Cardiomyocytes from Human iPS Cells Requires Precise Modulation of BMP and WNT Signaling , 2014, Stem Cell Reviews and Reports.
[69] K. Node,et al. Endothelin‐1 Induces Myofibrillar Disarray and Contractile Vector Variability in Hypertrophic Cardiomyopathy–Induced Pluripotent Stem Cell–Derived Cardiomyocytes , 2014, Journal of the American Heart Association.
[70] K. Kolaja,et al. Disease modeling and phenotypic drug screening for diabetic cardiomyopathy using human induced pluripotent stem cells. , 2014, Cell reports.
[71] N. Risch,et al. Estimating genotype error rates from high-coverage next-generation sequence data , 2014, Genome research.
[72] Robert Zweigerdt,et al. Controlling Expansion and Cardiomyogenic Differentiation of Human Pluripotent Stem Cells in Scalable Suspension Culture , 2014, Stem cell reports.
[73] D. Arnett,et al. RNA Expression Profiling of Human iPSC-Derived Cardiomyocytes in a Cardiac Hypertrophy Model , 2014, PloS one.
[74] P. Burridge,et al. Characterization of the molecular mechanisms underlying increased ischemic damage in the aldehyde dehydrogenase 2 genetic polymorphism using a human induced pluripotent stem cell model system , 2014, Science Translational Medicine.
[75] Lei Yang,et al. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells , 2014, Cardiovascular research.
[76] Roger A. Pedersen,et al. NANOG and CDX2 pattern distinct subtypes of human mesoderm during exit from pluripotency. , 2014, Cell stem cell.
[77] A. Clarke. Managing the ethical challenges of next-generation sequencing in genomic medicine. , 2014, British medical bulletin.
[78] C. Thermes,et al. Ten years of next-generation sequencing technology. , 2014, Trends in genetics : TIG.
[79] Benjamin D. Simons,et al. Early lineage restriction in temporally distinct populations of Mesp1 progenitors during mammalian heart development , 2014, Nature Cell Biology.
[80] Dietrich Rebholz-Schuhmann,et al. Biological network extraction from scientific literature: state of the art and challenges , 2014, Briefings Bioinform..
[81] K. Red-Horse,et al. Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes as an In Vitro Model for Coxsackievirus B3–Induced Myocarditis and Antiviral Drug Screening Platform , 2014, Circulation research.
[82] O. Abilez,et al. Effect of human donor cell source on differentiation and function of cardiac induced pluripotent stem cells. , 2014, Journal of the American College of Cardiology.
[83] M. Kay,et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. , 2014, Journal of the American College of Cardiology.
[84] Praveen Shukla,et al. Chemically defined generation of human cardiomyocytes , 2014, Nature Methods.
[85] C. Gersbach,et al. Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine , 2014, Expert opinion on therapeutic targets.
[86] G. Fishman,et al. Identification and Purification of Human Induced Pluripotent Stem Cell-Derived Atrial-Like Cardiomyocytes Based on Sarcolipin Expression , 2014, PloS one.
[87] Kun Zhang,et al. Whole-genome sequencing analysis reveals high specificity of CRISPR/Cas9 and TALEN-based genome editing in human iPSCs. , 2014, Cell stem cell.
[88] Feng Chen,et al. Targeted gene correction minimally impacts whole-genome mutational load in human-disease-specific induced pluripotent stem cell clones. , 2014, Cell stem cell.
[89] Chad A. Cowan,et al. Low incidence of off-target mutations in individual CRISPR-Cas9 and TALEN targeted human stem cell clones detected by whole-genome sequencing. , 2014, Cell stem cell.
[90] C. Abi Khalil. The emerging role of epigenetics in cardiovascular disease , 2014, Therapeutic advances in chronic disease.
[91] E. Knapik,et al. Gremlin 2 Promotes Differentiation of Embryonic Stem Cells to Atrial Fate by Activation of the JNK Signaling Pathway , 2014, Stem cells.
[92] George M. Church,et al. CRISPR/Cas9‐Directed Genome Editing of Cultured Cells , 2014, Current protocols in molecular biology.
[93] Ulf Leser,et al. Trends in Genome Compression , 2014 .
[94] M. Yacoub,et al. The role of endothelin-1 in pulmonary arterial hypertension , 2014, Global cardiology science & practice.
[95] Paul W. Burridge,et al. Human Stem Cells for Modeling Heart Disease and for Drug Discovery , 2014, Science Translational Medicine.
[96] D. Zheng,et al. DNA Methylation is Developmentally Regulated for Genes Essential for Cardiogenesis , 2014, Journal of the American Heart Association.
[97] Daniel J. Gaffney,et al. Genetic Background Drives Transcriptional Variation in Human Induced Pluripotent Stem Cells , 2014, PLoS genetics.
[98] E. Lander,et al. Development and Applications of CRISPR-Cas9 for Genome Engineering , 2014, Cell.
[99] Y. Higaki,et al. Functional analysis of iPSC-derived myocytes from a patient with carnitine palmitoyltransferase II deficiency. , 2014, Biochemical and biophysical research communications.
[100] Gang Wang,et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies , 2014 .
[101] Jose M Polo,et al. Phases of reprogramming. , 2014, Stem cell research.
[102] Martin J. Aryee,et al. Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing , 2014, Nature Biotechnology.
[103] V. Iyer,et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects , 2014, Nature Methods.
[104] David A. Scott,et al. Genome-wide binding of the CRISPR endonuclease Cas9 in mammalian cells , 2014, Nature Biotechnology.
[105] Desheng Liang,et al. TALE nickase mediates high efficient targeted transgene integration at the human multi-copy ribosomal DNA locus. , 2014, Biochemical and biophysical research communications.
[106] E. Sernagor,et al. An Induced Pluripotent Stem Cell Model of Hypoplastic Left Heart Syndrome (HLHS) Reveals Multiple Expression and Functional Differences in HLHS‐Derived Cardiac Myocytes , 2014, Stem cells translational medicine.
[107] Ronald A. Li,et al. A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. , 2014, Stem cells and development.
[108] J. Keith Joung,et al. Broad Specificity Profiling of TALENs Results in Engineered Nucleases With Improved DNA Cleavage Specificity , 2014, Nature Methods.
[109] Lil Pabon,et al. Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes , 2014, Circulation research.
[110] Ravi Iyengar,et al. Small Molecule‐Mediated Directed Differentiation of Human Embryonic Stem Cells Toward Ventricular Cardiomyocytes , 2014, Stem cells translational medicine.
[111] K. Morgan,et al. Allele-specific RNA interference rescues the long-QT syndrome phenotype in human-induced pluripotency stem cell cardiomyocytes , 2013, European heart journal.
[112] Joseph C. Wu,et al. Second generation codon optimized minicircle (CoMiC) for nonviral reprogramming of human adult fibroblasts. , 2014, Methods in molecular biology.
[113] David R. Liu,et al. Determining the specificities of TALENs, Cas9, and other genome-editing enzymes. , 2014, Methods in enzymology.
[114] Azra Fatima,et al. The Disease-Specific Phenotype in Cardiomyocytes Derived from Induced Pluripotent Stem Cells of Two Long QT Syndrome Type 3 Patients , 2013, PloS one.
[115] L. Gepstein,et al. Modeling of Arrhythmogenic Right Ventricular Cardiomyopathy With Human Induced Pluripotent Stem Cells , 2013, Circulation. Cardiovascular genetics.
[116] Jiangnan Yu,et al. Non‐Viral Co‐Delivery of the Four Yamanaka Factors for Generation of Human Induced Pluripotent Stem Cells via Calcium Phosphate Nanocomposite Particles , 2013 .
[117] Joseph C. Wu,et al. Patient-specific stem cells and cardiovascular drug discovery. , 2013, JAMA.
[118] Kumaraswamy Nanthakumar,et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues , 2013, Proceedings of the National Academy of Sciences.
[119] Simona Casini,et al. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome , 2013, The EMBO journal.
[120] Luke A. Gilbert,et al. CRISPR interference (CRISPRi) for sequence-specific control of gene expression , 2013, Nature Protocols.
[121] Teng Hong Tan,et al. Modeling type 3 long QT syndrome with cardiomyocytes derived from patient-specific induced pluripotent stem cells. , 2013, International journal of cardiology.
[122] Zohar Mukamel,et al. Deterministic direct reprogramming of somatic cells to pluripotency , 2013, Nature.
[123] M Miragoli,et al. CaMKII inhibition rectifies arrhythmic phenotype in a patient-specific model of catecholaminergic polymorphic ventricular tachycardia , 2013, Cell Death and Disease.
[124] Natsuyo Aoyama,et al. Phenotypic Screening with Human iPS Cell–Derived Cardiomyocytes , 2013, Journal of biomolecular screening.
[125] Donald M Bers,et al. Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.
[126] P. Shannon,et al. Fetal reprogramming and senescence in hypoplastic left heart syndrome and in human pluripotent stem cells during cardiac differentiation. , 2013, The American journal of pathology.
[127] Waqar Hussain,et al. Reproducible culture and differentiation of mouse embryonic stem cells using an automated microwell platform☆ , 2013, Biochemical engineering journal.
[128] H. Deng,et al. Pluripotent Stem Cells Induced from Mouse Somatic Cells by Small-Molecule Compounds , 2013, Science.
[129] M. Hayden,et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children , 2013, Pediatric blood & cancer.
[130] M. Morad,et al. Ca2+ signaling in human induced pluripotent stem cell-derived cardiomyocytes (iPS-CM) from normal and catecholaminergic polymorphic ventricular tachycardia (CPVT)-afflicted subjects. , 2013, Cell calcium.
[131] R. Jaenisch,et al. One-Step Generation of Mice Carrying Reporter and Conditional Alleles by CRISPR/Cas-Mediated Genome Engineering , 2013, Cell.
[132] A. Muotri,et al. Efficient generation of human iPSCs by a synthetic self-replicative RNA. , 2013, Cell stem cell.
[133] C. Mummery,et al. Generation of induced pluripotent stem cells from human foetal fibroblasts using the Sleeping Beauty transposon gene delivery system. , 2013, Differentiation; research in biological diversity.
[134] C. Barbas,et al. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. , 2013, Trends in biotechnology.
[135] Kumaraswamy Nanthakumar,et al. Biowire: a New Platform for Maturation of Human Pluripotent Stem Cell Derived Cardiomyocytes Pubmed Central Canada , 2022 .
[136] Gary L. Mantalas,et al. Overview of High Throughput Sequencing Technologies to Elucidate Molecular Pathways in Cardiovascular Diseases , 2013, Circulation research.
[137] Zachariah Gompert,et al. Population genomics based on low coverage sequencing: how low should we go? , 2013, Molecular ecology.
[138] Wolfgang Wagner,et al. To Clone or Not to Clone? Induced Pluripotent Stem Cells Can Be Generated in Bulk Culture , 2013, PloS one.
[139] M. Snyder,et al. iPOP goes the world: integrated personalized Omics profiling and the road toward improved health care. , 2013, Chemistry & biology.
[140] M. Kay,et al. A mini-intronic plasmid (MIP): a novel robust transgene expression vector in vivo and in vitro. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.
[141] W. Frishman. β-Adrenergic Blockade in Cardiovascular Disease , 2013, Journal of cardiovascular pharmacology and therapeutics.
[142] Da-Zhi Wang,et al. MicroRNA-22 Regulates Cardiac Hypertrophy and Remodeling in Response to Stress , 2013, Circulation research.
[143] Donald M Bers,et al. Drug Screening Using a Library of Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes Reveals Disease-Specific Patterns of Cardiotoxicity , 2013, Circulation.
[144] Philip Wong,et al. Generation of patient-specific induced pluripotent stem cell-derived cardiomyocytes as a cellular model of arrhythmogenic right ventricular cardiomyopathy. , 2013, European heart journal.
[145] M. Pirmohamed,et al. Expanding Role of Pharmacogenomics in the Management of Cardiovascular Disorders , 2013, American Journal of Cardiovascular Drugs.
[146] P. Sham,et al. Patient-specific induced-pluripotent stem cells-derived cardiomyocytes recapitulate the pathogenic phenotypes of dilated cardiomyopathy due to a novel DES mutation identified by whole exome sequencing. , 2013, Human molecular genetics.
[147] O. Cohen-Haguenauer,et al. Send Orders of Reprints at Reprints@benthamscience.net Technological Overview of Ips Induction from Human Adult Somatic Cells , 2022 .
[148] Hao Yan,et al. DNA Gridiron Nanostructures Based on Four-Arm Junctions , 2013, Science.
[149] Derrick J. Rossi,et al. Reprogramming human fibroblasts to pluripotency using modified mRNA , 2013, Nature Protocols.
[150] S. Yamanaka,et al. An Efficient Nonviral Method to Generate Integration‐Free Human‐Induced Pluripotent Stem Cells from Cord Blood and Peripheral Blood Cells , 2013, Stem cells.
[151] R. Pretorius,et al. Reducing the risk of adverse drug events in older adults. , 2013, American family physician.
[152] Shinya Yamanaka,et al. Ultrastructural maturation of human-induced pluripotent stem cell-derived cardiomyocytes in a long-term culture. , 2013, Circulation journal : official journal of the Japanese Circulation Society.
[153] Kevin Kim,et al. A TALEN genome-editing system for generating human stem cell-based disease models. , 2013, Cell stem cell.
[154] Carlos F. Barbas,et al. A comprehensive approach to zinc-finger recombinase customization enables genomic targeting in human cells , 2013, Nucleic acids research.
[155] H. McLeod,et al. Pharmacogenomics as a risk mitigation strategy for chemotherapeutic cardiotoxicity. , 2013, Pharmacogenomics.
[156] Euan A Ashley,et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. , 2013, Cell stem cell.
[157] M. Suematsu,et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. , 2013, Cell stem cell.
[158] Ivan Rusyn,et al. Multiparameter In Vitro Assessment of Compound Effects on Cardiomyocyte Physiology Using iPSC Cells , 2013, Journal of biomolecular screening.
[159] Gordon Keller,et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics , 2013, The Journal of general physiology.
[160] H. Calkins,et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs , 2012, Nature.
[161] Divya Rajamohan,et al. Current status of drug screening and disease modelling in human pluripotent stem cells , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.
[162] 遠山 周吾. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes , 2013 .
[163] P. Burridge,et al. Generation of human iPSCs from human peripheral blood mononuclear cells using non-integrative Sendai virus in chemically defined conditions. , 2013, Methods in molecular biology.
[164] H. R. Lu,et al. Repolarization reserve determines drug responses in human pluripotent stem cell derived cardiomyocytes. , 2013, Stem cell research.
[165] Hee Cheol Cho,et al. Direct conversion of quiescent cardiomyocytes to pacemaker cells by expression of Tbx18 , 2012, Nature Biotechnology.
[166] Yi Zhang,et al. Embryonic stem cell and induced pluripotent stem cell: an epigenetic perspective , 2012, Cell Research.
[167] Tobias Schmidt,et al. A ligation-independent cloning technique for high-throughput assembly of transcription activator–like effector genes , 2012, Nature Biotechnology.
[168] P. Alagona,et al. The worldwide environment of cardiovascular disease: prevalence, diagnosis, therapy, and policy issues: a report from the American College of Cardiology. , 2012, Journal of the American College of Cardiology.
[169] Barry Merriman,et al. Progress in Ion Torrent semiconductor chip based sequencing , 2012, Electrophoresis.
[170] C. Siu,et al. Modeling of lamin A/C mutation premature cardiac aging using patient-specific induced pluripotent stem cells , 2012, Aging.
[171] Linzhao Cheng,et al. Generation of integration-free human induced pluripotent stem cells from postnatal blood mononuclear cells by plasmid vector expression , 2012, Nature Protocols.
[172] Siqun Xu,et al. © The American Society of Gene & Cell Therapy original article The Extragenic Spacer Length Between the 5 ′ and 3 ′ Ends of the Transgene Expression Cassette Affects Transgene Silencing From Plasmid-based Vectors , 2012 .
[173] W. Wong,et al. Activation of Innate Immunity Is Required for Efficient Nuclear Reprogramming , 2012, Cell.
[174] G. Lyons,et al. Extracellular Matrix Promotes Highly Efficient Cardiac Differentiation of Human Pluripotent Stem Cells: The Matrix Sandwich Method , 2012, Circulation research.
[175] A. Kuroiwa,et al. Fibroblast growth factor 10 gene regulation in the second heart field by Tbx1, Nkx2-5, and Islet1 reveals a genetic switch for down-regulation in the myocardium , 2012, Proceedings of the National Academy of Sciences.
[176] Carlos F. Barbas,et al. Chimeric TALE recombinases with programmable DNA sequence specificity , 2012, Nucleic acids research.
[177] Xi-rong Guo,et al. Feeder-Free Derivation of Human Induced Pluripotent Stem Cells with Messenger RNA , 2012, Scientific Reports.
[178] Michael Glikson,et al. Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. , 2012, Journal of the American College of Cardiology.
[179] Katriina Aalto-Setälä,et al. Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Reveals Early and Delayed Afterdepolarizations , 2012, PloS one.
[180] P. Elliott,et al. Genetics and metabolic cardiomyopathies , 2012, Herz.
[181] An integrated chip for the high-throughput synthesis of transcription activator-like effectors. , 2012, Angewandte Chemie.
[182] J. Doudna,et al. A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.
[183] Michael D. Schneider,et al. Development of High Content Imaging Methods for Cell Death Detection in Human Pluripotent Stem Cell-Derived Cardiomyocytes , 2012, Journal of Cardiovascular Translational Research.
[184] M. Kowalski,et al. Controlling Embryonic Stem Cell Growth and Differentiation by Automation , 2012, Journal of biomolecular screening.
[185] G. Salama,et al. High-purity enrichment of functional cardiovascular cells from human iPS cells. , 2012, Cardiovascular research.
[186] Anna M. McGeachy,et al. The ribosome profiling strategy for monitoring translation in vivo by deep sequencing of ribosome-protected mRNA fragments , 2012, Nature Protocols.
[187] Ulf Leser,et al. Data Management Challenges in Next Generation Sequencing , 2012, Datenbank-Spektrum.
[188] H. Swerdlow,et al. A tale of three next generation sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq sequencers , 2012, BMC Genomics.
[189] Lin Liu,et al. Comparison of Next-Generation Sequencing Systems , 2012, Journal of biomedicine & biotechnology.
[190] D. Kass,et al. Animal models of heart failure: a scientific statement from the American Heart Association. , 2012, Circulation research.
[191] Sean P. Palecek,et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling , 2012, Proceedings of the National Academy of Sciences.
[192] D. Rao,et al. Whole-exome Sequencing and an iPSC-Derived Cardiomyocyte Model Provides a Powerful Platform for Gene Discovery in Left Ventricular Hypertrophy , 2012, Front. Gene..
[193] C. Denning,et al. In Vitro Uses of Human Pluripotent Stem Cell-Derived Cardiomyocytes , 2012, Journal of Cardiovascular Translational Research.
[194] Ofer Binah,et al. Cardiomyocytes derived from human pluripotent stem cells for drug screening. , 2012, Pharmacology & therapeutics.
[195] M. Hayden,et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[196] Euan A. Ashley,et al. Patient-Specific Induced Pluripotent Stem Cells as a Model for Familial Dilated Cardiomyopathy , 2012, Science Translational Medicine.
[197] Natalia B. Ivanova,et al. Distinct lineage specification roles for NANOG, OCT4, and SOX2 in human embryonic stem cells. , 2012, Cell stem cell.
[198] Laura Iop,et al. Dantrolene rescues arrhythmogenic RYR2 defect in a patient-specific stem cell model of catecholaminergic polymorphic ventricular tachycardia , 2012, EMBO molecular medicine.
[199] Ofer Binah,et al. Cardiomyocytes generated from CPVTD307H patients are arrhythmogenic in response to β-adrenergic stimulation , 2012, Journal of cellular and molecular medicine.
[200] A. Franke,et al. DNA methylome analysis using short bisulfite sequencing data , 2012, Nature Methods.
[201] W. McKenna,et al. Genetics of inherited cardiomyopathy. , 2012, European heart journal.
[202] Gordon Keller,et al. Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming. , 2012, Cell stem cell.
[203] A. Nagy,et al. EMBRYONIC STEM CELLS / INDUCED PLURIPOTENT STEM CELLS Concise Review : Embryonic Stem Cells Versus Induced Pluripotent Stem Cells : The Game Is On , 2011 .
[204] J. Bilić,et al. Concise Review: Induced Pluripotent Stem Cells Versus Embryonic Stem Cells: Close Enough or Yet Too Far Apart? , 2012, Stem cells.
[205] R. Thomas,et al. Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. , 2012, Advances in protein chemistry and structural biology.
[206] Euan A Ashley,et al. Performance comparison of whole-genome sequencing platforms , 2011, Nature Biotechnology.
[207] Y. Chien,et al. Human Pompe disease-induced pluripotent stem cells for pathogenesis modeling, drug testing and disease marker identification. , 2011, Human molecular genetics.
[208] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[209] Barry J Maron,et al. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines , 2011, Circulation.
[210] Barry J Maron,et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2011, The Journal of thoracic and cardiovascular surgery.
[211] Azra Fatima,et al. In vitro Modeling of Ryanodine Receptor 2 Dysfunction Using Human Induced Pluripotent Stem Cells , 2011, Cellular Physiology and Biochemistry.
[212] Gordon Keller,et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells , 2011, Nature Biotechnology.
[213] R. Russell,et al. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment , 2011, Current cardiology reviews.
[214] M. Oshimura,et al. Integration-Free iPS Cells Engineered Using Human Artificial Chromosome Vectors , 2011, PloS one.
[215] Ssang-Goo Cho,et al. The generation of iPS cells using non-viral magnetic nanoparticle based transfection. , 2011, Biomaterials.
[216] Shinya Yamanaka,et al. Efficient and Scalable Purification of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression , 2011, PloS one.
[217] Naoki Nishishita,et al. Efficient generation of transgene-free human induced pluripotent stem cells (iPSCs) by temperature-sensitive Sendai virus vectors , 2011, Proceedings of the National Academy of Sciences.
[218] Tina Hernandez-Boussard,et al. Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.
[219] N. Terada,et al. Induced pluripotent stem cells as a next-generation biomedical interface , 2011, Laboratory Investigation.
[220] P. Oliveira,et al. Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. , 2011, Current pharmaceutical design.
[221] H. Steven Wiley,et al. Characterization and improvement of RNA-Seq precision in quantitative transcript expression profiling , 2011, Bioinform..
[222] Mitsugu Sekimoto,et al. Reprogramming of mouse and human cells to pluripotency using mature microRNAs. , 2011, Cell stem cell.
[223] E. Quigley,et al. Cisapride: What can we learn from the rise and fall of a prokinetic? , 2011, Journal of digestive diseases.
[224] A. Y. Lu,et al. Pharmacogenetics, Pharmacogenomics, and Individualized Medicine , 2011, Pharmacological Reviews.
[225] William Sun,et al. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells. , 2011, Cardiovascular research.
[226] Xuan Yuan,et al. A Universal System for Highly Efficient Cardiac Differentiation of Human Induced Pluripotent Stem Cells That Eliminates Interline Variability , 2011, PloS one.
[227] Stéphanie Boué,et al. Methods for making induced pluripotent stem cells: reprogramming à la carte , 2011, Nature Reviews Genetics.
[228] Jonathan A. Bernstein,et al. Using iPS cells to investigate cardiac phenotypes in patients with Timothy Syndrome , 2011, Nature.
[229] Lior Gepstein,et al. Modelling the long QT syndrome with induced pluripotent stem cells , 2011, Nature.
[230] Riitta Lahesmaa,et al. Copy number variation and selection during reprogramming to pluripotency , 2011, Nature.
[231] Divya Rajamohan,et al. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation , 2011, European heart journal.
[232] Hanns Lochmüller,et al. Two new protocols to enhance the production and isolation of human induced pluripotent stem cell lines. , 2011, Stem cell research.
[233] Junying Yu,et al. Efficient Feeder-Free Episomal Reprogramming with Small Molecules , 2011, PloS one.
[234] Elaine R. Mardis,et al. A decade’s perspective on DNA sequencing technology , 2011, Nature.
[235] Gordon Keller,et al. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. , 2011, Cell stem cell.
[236] Tomohide Takaya. Identification of p300-targeted acetylated residues in GATA4 during hypertrophic responses in cardiac myocytes , 2011 .
[237] Peter G Schultz,et al. Stepwise chemically induced cardiomyocyte specification of human embryonic stem cells. , 2011, Angewandte Chemie.
[238] Weiqi Zhang,et al. Generation of iPSCs from mouse fibroblasts with a single gene, Oct4, and small molecules , 2011, Cell Research.
[239] Shinya Yamanaka,et al. Induced Pluripotent Stem Cells , 2011, SpringerBriefs in Stem Cells.
[240] Michael T Longaker,et al. Generation of adult human induced pluripotent stem cells using nonviral minicircle DNA vectors , 2011, Nature Protocols.
[241] Russell M Gordley,et al. Structure-guided reprogramming of serine recombinase DNA sequence specificity , 2010, Proceedings of the National Academy of Sciences.
[242] Alexander Meissner,et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. , 2010, Cell stem cell.
[243] K. Hochedlinger,et al. Induced pluripotency: history, mechanisms, and applications. , 2010, Genes & development.
[244] Karl-Ludwig Laugwitz,et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. , 2010, New England Journal of Medicine.
[245] Johnf . Thompson,et al. Single Molecule Sequencing with a HeliScope Genetic Analysis System , 2010, Current protocols in molecular biology.
[246] Wei-Zhong Zhu,et al. Neuregulin/ErbB Signaling Regulates Cardiac Subtype Specification in Differentiating Human Embryonic Stem Cells , 2010, Circulation research.
[247] M. Snyder,et al. ChIP‐Seq: A Method for Global Identification of Regulatory Elements in the Genome , 2010, Current protocols in molecular biology.
[248] Olga K Afanasiev,et al. Endogenous Wnt/β-Catenin Signaling Is Required for Cardiac Differentiation in Human Embryonic Stem Cells , 2010, PloS one.
[249] B. Tomlinson,et al. ABCG2 Polymorphism Is Associated With the Low‐Density Lipoprotein Cholesterol Response to Rosuvastatin , 2010, Clinical pharmacology and therapeutics.
[250] P. Itsykson,et al. Derivation, propagation and controlled differentiation of human embryonic stem cells in suspension , 2010, Nature Biotechnology.
[251] Lei Yang,et al. Patient-specific induced pluripotent stem cell derived models of LEOPARD syndrome , 2010, Nature.
[252] Deepak M. Gupta,et al. A nonviral minicircle vector for deriving human iPS cells , 2010, Nature Methods.
[253] J. Monshouwer-Kloots,et al. Identification of cell surface proteins for antibody-based selection of human embryonic stem cell-derived cardiomyocytes. , 2010, Journal of proteome research.
[254] S. Rahman,et al. Prevalence and natural history of heart disease in adults with primary mitochondrial respiratory chain disease , 2010, European journal of heart failure.
[255] Jin-Soo Kim,et al. Genome editing with modularly assembled zinc-finger nucleases , 2010, Nature Methods.
[256] E. Sasaki,et al. Nongenetic method for purifying stem cell–derived cardiomyocytes , 2010, Nature Methods.
[257] Norman Honbo,et al. Doxorubicin Cardiomyopathy , 2009, Cardiology.
[258] Wenbo Zhou,et al. Adenoviral Gene Delivery Can Reprogram Human Fibroblasts to Induced Pluripotent Stem Cells , 2009, Stem cells.
[259] Robert Passier,et al. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery. , 2009, Trends in pharmacological sciences.
[260] M. Hasegawa,et al. Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome , 2009, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[261] S. Yamanaka,et al. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells. , 2009, Biochemical and biophysical research communications.
[262] Jian-Fu Chen,et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. , 2009, The Journal of clinical investigation.
[263] Y. Kaneda,et al. A histone H3 lysine 36 trimethyltransferase links Nkx2-5 to Wolf–Hirschhorn syndrome , 2009, Nature.
[264] Robert Lanza,et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. , 2009, Cell stem cell.
[265] N. Lévêque,et al. Viral causes of human myocarditis. , 2009, Archives of cardiovascular diseases.
[266] R. Hajjar,et al. Cardionomics: a new integrative approach for screening cardiotoxicity of drug candidates , 2009, Expert opinion on drug metabolism & toxicology.
[267] Thomas J. Hardcastle,et al. Chromosomal instability determines taxane response , 2009, Proceedings of the National Academy of Sciences.
[268] R. Stewart,et al. Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences , 2009, Science.
[269] Dong Wook Han,et al. Generation of induced pluripotent stem cells using recombinant proteins. , 2009, Cell stem cell.
[270] David J. Williams,et al. Automated, scalable culture of human embryonic stem cells in feeder‐free conditions , 2009, Biotechnology and bioengineering.
[271] T. Cantz,et al. Induced pluripotent stem cells generated without viral integration , 2009, Hepatology.
[272] K. Woltjen,et al. Virus free induction of pluripotency and subsequent excision of reprogramming factors , 2009, Nature.
[273] Rudolf Jaenisch,et al. Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors , 2009, Cell.
[274] D. Rossi,et al. Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 , 2009, Leukemia.
[275] N. Shanks,et al. Are animal models predictive for humans? , 2009, Philosophy, ethics, and humanities in medicine : PEHM.
[276] N. Avent,et al. Toxicity testing: the search for an in vitro alternative to animal testing , 2009, British journal of biomedical science.
[277] Z. Storchová,et al. The consequences of tetraploidy and aneuploidy , 2008, Journal of Cell Science.
[278] Paul S Price,et al. Characterizing interspecies uncertainty using data from studies of anti-neoplastic agents in animals and humans. , 2008, Toxicology and applied pharmacology.
[279] Wenjun Guo,et al. Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2 , 2008, Nature Biotechnology.
[280] George Q. Daley,et al. Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.
[281] Hynek Wichterle,et al. Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons , 2008, Science.
[282] Michael Kyba,et al. Mesp1 acts as a master regulator of multipotent cardiovascular progenitor specification. , 2008, Cell stem cell.
[283] Z. Herceg,et al. Epigenetic interplay between histone modifications and DNA methylation in gene silencing. , 2008, Mutation research.
[284] Eric D. Adler,et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population , 2008, Nature.
[285] T. Kita,et al. Identification of p300-targeted Acetylated Residues in GATA4 during Hypertrophic Responses in Cardiac Myocytes*♦ , 2008, Journal of Biological Chemistry.
[286] Jim Stalker,et al. A Novel CpG Island Set Identifies Tissue-Specific Methylation at Developmental Gene Loci , 2008, PLoS biology.
[287] Wolf-Dietrich Heyer,et al. Homologous recombination in DNA repair and DNA damage tolerance , 2008, Cell Research.
[288] Takashi Aoi,et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts , 2008, Nature Biotechnology.
[289] Masafumi Okumura,et al. Heterogeneity of pluripotent marker gene expression in colonies generated in human iPS cell induction culture. , 2008, Stem cell research.
[290] Shulan Tian,et al. Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells , 2007, Science.
[291] T. Ichisaka,et al. Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors , 2007, Cell.
[292] Lila R Collins,et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts , 2007, Nature Biotechnology.
[293] John M. Haynes,et al. Embryonic stem cells as a source of models for drug discovery , 2007, Nature Reviews Drug Discovery.
[294] D. Loebel,et al. Gene function in mouse embryogenesis: get set for gastrulation , 2007, Nature Reviews Genetics.
[295] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[296] Barry J Maron,et al. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interd , 2006, Circulation.
[297] T. Self,et al. Common culture conditions for maintenance and cardiomyocyte differentiation of the human embryonic stem cell lines, BG01 and HUES-7. , 2006, The International journal of developmental biology.
[298] Robert Zweigerdt,et al. Differentiation and lineage selection of mouse embryonic stem cells in a stirred bench scale bioreactor with automated process control. , 2005, Biotechnology and bioengineering.
[299] M. Pfreundschuh,et al. NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.
[300] Younghee Lee,et al. Basic fibroblast growth factor activates ERK and induces c-fos in human embryonic stem cell line MizhES1. , 2005, Stem cells and development.
[301] C. Macrae,et al. Animal models for arrhythmias. , 2005, Cardiovascular research.
[302] J. Itskovitz‐Eldor,et al. No Evidence for Infection of Human Embryonic Stem Cells by Feeder Cell–Derived Murine Leukemia Viruses , 2005, Stem cells.
[303] John McAnally,et al. BOP, a regulator of right ventricular heart development, is a direct transcriptional target of MEF2C in the developing heart , 2005, Development.
[304] A. Marian,et al. Pharmacogenetic study of statin therapy and cholesterol reduction. , 2005, Current atherosclerosis reports.
[305] M. Mercola,et al. Heart induction by Wnt antagonists depends on the homeodomain transcription factor Hex. , 2005, Genes & development.
[306] T. Meyer,et al. QT-screen: high-throughput cardiac safety pharmacology by extracellular electrophysiology on primary cardiac myocytes. , 2004, Assay and drug development technologies.
[307] D. Constam,et al. A gene network establishing polarity in the early mouse embryo. , 2004, Seminars in cell & developmental biology.
[308] E. Corwin. The Concept of Epigenetics and Its Role in the Development of Cardiovascular Disease: Commentary on “New and Emerging Theories of Cardiovascular Disease” , 2004, Biological research for nursing.
[309] Steffen Bauer,et al. Evidence for Inverse Effects of OATP‐C (SLC21A6) *5 and *1b Haplotypes on Pravastatin Kinetics , 2004, Clinical pharmacology and therapeutics.
[310] M. Kay,et al. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[311] R. Harvey,et al. Molecular pathways in myocardial development: a stem cell perspective. , 2003, Cardiovascular research.
[312] G. Dorn,et al. Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. , 2003, The Journal of clinical investigation.
[313] A. Bird,et al. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals , 2003, Nature Genetics.
[314] Chunhui Xu,et al. Characterization and Enrichment of Cardiomyocytes Derived From Human Embryonic Stem Cells , 2002, Circulation research.
[315] I. Komuro,et al. The Polycomb-group gene Rae28 sustains Nkx2.5/Csx expression and is essential for cardiac morphogenesis. , 2002, The Journal of clinical investigation.
[316] J. Schmitt,et al. A Murine Model of Holt-Oram Syndrome Defines Roles of the T-Box Transcription Factor Tbx5 in Cardiogenesis and Disease , 2001, Cell.
[317] Ryozo Nagai,et al. Tbx5 associates with Nkx2-5 and synergistically promotes cardiomyocyte differentiation , 2001, Nature Genetics.
[318] E. Kieff,et al. Maintenance of Epstein-Barr virus (EBV) oriP-based episomes requires EBV-encoded nuclear antigen-1 chromosome-binding domains, which can be replaced by high-mobility group-I or histone H1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[319] D M Roden,et al. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[320] D. Applegarth,et al. Incidence of Inborn Errors of Metabolism in British Columbia, 1969–1996 , 2000, Pediatrics.
[321] J. Thomson,et al. Embryonic stem cell lines derived from human blastocysts. , 1998, Science.
[322] G.E. Moore,et al. Cramming More Components Onto Integrated Circuits , 1998, Proceedings of the IEEE.
[323] D R Illingworth,et al. The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day. , 1997, The American journal of cardiology.
[324] R. Buller,et al. Vaccinia Virus B18R Gene Encodes a Type I Interferon-binding Protein That Blocks Interferon α Transmembrane Signaling (*) , 1995, The Journal of Biological Chemistry.
[325] F. Schoen,et al. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. , 1987, Circulation.
[326] L. Liu,et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.
[327] L. Liu,et al. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. , 1984, The Journal of biological chemistry.
[328] J. Gurdon,et al. Adult frogs derived from the nuclei of single somatic cells. , 1962, Developmental biology.